Nontraditional Products for Bacterial Infections in Clinical Development

Nontraditional Products for Bacterial Infections

This data visualization was updated in September 2018 with new data.

As of June 2018, an estimated 30 new nontraditional products1 with the potential to treat or prevent serious bacterial infections are in clinical development. Below is a snapshot of the current nontraditional products pipeline, based on publicly available information and informed by external experts. It is updated periodically as products advance or are known to drop out of development. Because this list is updated periodically, endnote numbers may not be sequential.

Please contact abxpipeline@pewtrusts.org with additions or updates.

September 2018 (PDF)  | September 2017 (PDF)  |  March 2017 (PDF)

A data visualization from
A data visualization from The Pew Charitable Trusts
Sorted by:
Z-A
A-Z

Note: The following drugs have been removed from the pipeline. They will be included in future updates if development resumes:

June 2018: ASN100, GEN 004, Group B Streptococcus vaccine, and VLA84 (IC84) were removed because they were no longer included in the research and development pipeline on the company’s website.

    September 2017: Cdiffense and Shigamab were removed during the September 2017 review because they were no longer included in the research and development pipeline on the company's website or discontinuation of development was announced through a company press release.

Endnotes

  1. Products listed here contain at least one component not previously approved in the United States. This pipeline is limited to products with the potential to treat or prevent infections caused by bacterial pathogens considered by the Centers for Disease Control and Prevention to be urgent, serious, or concerning threats (CDC, “Antibiotic Resistance Threats in the United States, 2013,” Sept. 16, 2013, https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf). All analyses were limited to systemic products (drugs that work throughout the body) and therapies to treat Clostridium difficile-associated disease. We excluded drugs to treat mycobacterial infections, such as tuberculosis and Mycobacterium avium complex, Helicobacter pylori, and biothreat pathogens. Also excluded were locally acting therapies such as topical, ophthalmic, and inhaled products. Many of these products probably will not be used as a stand-alone treatment, but as an adjunctive to standard-of-care antibiotics.
  2. Based on the most advanced development phase for any indication according to trials registered in http://www.clinicaltrials.gov, unless direct communication from the company indicated differently. If no trials were included in clinicaltrials.gov, the phase listed on the company website or provided directly by the company is noted.
  3. Based on clinical trials currently registered in http://www.clinicaltrials.gov unless otherwise noted.
  4. Registered in http://www.clinicaltrials.gov but with no current study sites within the United States.
  5. Ribaxamase is a β-lactamase, which is given orally and prophylactically with an IV antibiotic. Ribaxamase degrades antibiotics in the gastrointestinal tract to minimize collateral damage to the gut microbiome and prevent occurrence of C. difficile. DAV132 is an activated charcoal approach, which is given prophylactically and acts to absorb antibiotics in the GI tract to minimize damage to the gut microbiome and prevent the occurrence of C. difficile. .
  6. Information obtained from the company via a corporate website, news release, and/or direct company communication.
  7. Vaccines for S. pneumoniae have been approved and widely used. The products in development listed in this table have the potential for expanded serotype coverage.
Antibiotic Development
Antibiotic Development
Article

Tracking the Pipeline of Antibiotics in Development

Quick View
Article

This collection page was updated in December 2017 with new content. Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. A majority of doctors have encountered patients with infections that do not respond to available treatments, and when new drugs come to market bacteria can quickly develop resistance. According to a report from the Centers for Disease Control and Prevention, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and at least 23,000 die as a result. A sustained and robust pipeline of new antibacterial drugs and novel therapies is critical to ensure that new interventions keep pace with these evolving pathogens.

Antibiotics
Antibiotics
Issue Brief

Nontraditional Products in Development to Combat Bacterial Infections

Because the conventional antibiotics pipeline remains so thin, finding new approaches is critical

Quick View
Issue Brief

While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed.